Hsu, Jack

Hsu, Jack

Clinical Assistant Professor

Positions

Hematology and Oncology Fellow, University of Medicine and Dentistry of New Jersey
Resident, University of Medicine and Dentistry of New Jersey
Internship, University of Medicine and Dentistry of New Jersey
Faculty, Hematology and Oncology , Medicine 2007 -
Clinical Assistant Professor, Hematology and Oncology , Medicine 2007 -

research areas

Leukemia and Stem Cell Transplantation

has course role

home department

Hematology and Oncology Department

selected publications

letter
- Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes. British Journal of Haematology. 2020
academic article
- Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia. American Journal of Hematology. 608-619. 2023
- Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. Journal of Clinical Oncology. JCO2001739. 2021
- Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial. Frontiers in Immunology. 700045. 2021
- Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. Leukemia & Lymphoma. 1-10. 2020
- Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield. Blood Advances. 706-716. 2020
- Dietary intake and Diet Quality of Hematopoietic Stem Cell Transplant Survivors. Biology of Blood and Marrow Transplantation. 2020
- Collection of Peripheral Blood Progenitor Cells in One Day is Associated with Decreased Donor Toxicity compared to Two Days in Unrelated Donors. Biology of Blood and Marrow Transplantation. 2020
- Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. Biology of Blood and Marrow Transplantation. 2019
- A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients. Blood Advances. 2019
- Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Advances. 2018
- Efficacy of Micafungin for the Treatment of Invasive Candidiasis and Candidaemia in Patients With Neutropenia. Mycoses. 61:331-336. 2018
- Poor Peripheral Blood Stem Cell Mobilization Affects Long-Term Outcomes in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. Journal of Clinical Apheresis. 33:29-37. 2018
- Poor Peripheral Blood Stem Cell Mobilization Affects Long-Term Outcomes in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. Journal of Clinical Apheresis. 33:29-37. 2018
- Poor Peripheral Blood Stem Cell Mobilization Affects Long-Term Outcomes in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. Journal of Clinical Apheresis. 33:29-37. 2018
- Pharmacokinetic and clinical outcomes when ideal body weight is used to dose busulfan in obese hematopoietic stem cell transplant recipients. 2018
- Minimal Residual Disease By Either Flow Cytometry or Cytogenetics Prior to An Allogeneic Hematopoietic Stem Cell Transplant Is Associated With Poor Outcome in Acute Myeloid Leukemia. Blood Cancer Journal. 7. 2017
- Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. Biology of Blood and Marrow Transplantation. 23:767-775. 2017
- A Rare Case of Raoultella Planticola Urinary Tract Infection in An Immunocompromised Patient With Multiple Myeloma. Idcases. 8:9-11. 2017
- Autologous Hematopoietic Cell Transplantation for Hiv-Related Lymphoma: Results of the Bmt Ctn 0803/Amc 071 Trial. Blood. 128:1050-1058. 2016
- Effect of Melphalan 140 Mg/M(2) Vs 200 Mg/M(2) on Toxicities and Outcomes in Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Transplantation-a Single Center Experience. Clinical Transplantation. 30:894-900. 2016
- Metabolic Syndrome and Cardiovascular Disease After Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations From the Cibmtr and Ebmt. Biology of Blood and Marrow Transplantation. 22:1493-1503. 2016
- A New Model to Predict Remission Status in Aml Patients Based on Day 14 Bone Marrow Biopsy. Leukemia Research. 46:69-73. 2016
- Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. Journal of Clinical Oncology. 33:4167+. 2015
- Uric Acid and the Prediction Models of Tumor Lysis Syndrome in Aml. PLoS One. 10. 2015-03-01
- Poor Peripheral Blood Stem Cell Mobilization Correlates With Worse Long-Term Outcomes in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 21:S129. 2015-02-01
- Long-Term Survival and Late Effects Among One-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation. 21:151-158. 2015-01-01
- Race and Ethnicity Influences Collection of Granulocyte Colony-Stimulating Factor-Mobilized Peripheral Blood Progenitor Cells From Unrelated Donors, a Center for International Blood and Marrow Transplant Research Analysis. Biology of Blood and Marrow Transplantation. 21:165-171. 2015-01-01
- Second Solid Cancers After Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning. Biology of Blood and Marrow Transplantation. 20:1777-1784. 2014-11-01
- Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis. Journal of Clinical Oncology. 32:3264+. 2014-10-01
- Outcomes of Human Leukocyte Antigen-Matched Sibling Donor Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia: Myeloablative Versus Reduced-Intensity Conditioning Regimens. Biology of Blood and Marrow Transplantation. 20:1390-1398. 2014-09-01
- Elevated Incidence Of Chronic Myeloid Leukaemia In Immunosuppressed Solid Organ Transplant Recipients.. British Journal of Haematology. 166:619-21. 2014-08-01
- Tacrolimus/Sirolimus Vs Tacrolimus/Methotrexate as Gvhd Prophylaxis After Matched, Related Donor Allogeneic Hct. Blood. 124:1372-1377. 2014-08-01
- Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival. Biology of Blood and Marrow Transplantation. 2014
- Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma. Biology of Blood and Marrow Transplantation. 2014
- Avascular Necrosis of Bone After Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents. Biology of Blood and Marrow Transplantation. 20:587-592. 2014-04-01
- Does Total Body Irradiation Conditioning Improve Outcomes of Myeloablative Human Leukocyte Antigen-Identical Sibling Transplantations for Chronic Lymphocytic Leukemia?. Biology of Blood and Marrow Transplantation. 20:421-434. 2014-03-01
- Alk1 as a Novel Therapeutic Target for Cd30(+) T-Anaplastic Large Cell Lymphoma. Journal of the National Cancer Institute. 106. 2014-02-01
- Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma. Journal of Clinical Oncology. 31:3100+. 2013-09-01
- Impact of Pretransplantation Conditioning Regimens On Outcomes of Allogeneic Transplantation for Chemotherapy-Unresponsive Diffuse Large B Cell Lymphoma and Grade III Follicular Lymphoma. Biology of Blood and Marrow Transplantation. 19:746-753. 2013-05-01
- Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Unresponsive Mantle Cell Lymphoma: a Cohort Analysis From the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation. 19:625-631. 2013-04-01
- Association of Mannose Binding Lectin (Mbl) Levels and Invasive Fungal Disease (Ifd) in Hematologic Malignancy Patients Undergoing Hematopoietic Stem Cell Transplantation (Hsct) Or Receiving Chemotherapy. Biology of Blood and Marrow Transplantation. 19:S226-S227. 2013-02-01
- Autologous and Allogeneic Transplantation for Burkitt Lymphoma Outcomes and Changes in Utilization: a Report From the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation. 19:173-179. 2013-02-01
- The Role of Monoclonal Antibodies in the Treatment of Lymphomas. Expert Opinion on Biological Therapy. 13:227-239. 2013-02-01
- Late Effects in Hematopoietic Cell Transplant Recipients With Acquired Severe Aplastic Anemia: a Report From the Late Effects Working Committee of the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation. 18:1776-1784. 2012-12-01
- A Phase I Study of the Vascular Disrupting Combretastatin, Oxi4503, in Patients With Relapsed and Refractory Acute Myeloid Leukemia (Aml) and Myelodysplastic Syndromes (Mds). Blood. 120. 2012-11-01
- A Phase II Study of Allogeneic Transplantation for Older Patients With Aml in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From Calgb 100103/Bmt Ctn 0502. Blood. 120. 2012-11-01
- Higher Than Expected Incidence of Chronic Myeloid Leukemia in Solid Organ Transplant Recipients.. Blood. 120. 2012-11-01
- Peripheral Blood Cd34(+) Specific Donor Chimerism Analysis as An Early Indicator of Disease Relapse After Allogeneic Hematopoietic Stem Cell Transplant in Patients With Myelodysplastic Syndromes and Acute Myelogenous Leukemia.. Blood. 120. 2012-11-01
- Response Post-First Autologous Stem Cell Transplantation for Multiple Myeloma May Identify Patients Who Will Benefit From Tandem Transplants: a Single Center Prospective Phase II Study- An Update. Blood. 120. 2012-11-01
- Alternate Donor Hematopoietic Cell Transplantation (Hct) in Non-Hodgkin Lymphoma Using Lower Intensity Conditioning: a Report From the Cibmtr. Biology of Blood and Marrow Transplantation. 18:1036-1043. 2012-07-01
- Quality of Life, Social Challenges, and Psychosocial Support for Long-Term Survivors After Allogeneic Hematopoietic Stem-Cell Transplantation. Seminars in Hematology. 49:104-109. 2012-01-01
- Hematopoietic Stem Cell Transplantation: An Overview of Infection Risks and Epidemiology. Hematology/Oncology Clinics of North America. 25:101+. 2011-02-01
- Long-Term Outcome after Autologous Stem Cell Transplantation with Adequate Peripheral Blood Stem Cell Mobilization Using Plerixafor and G-CSF in Poor Mobilizer Lymphoma and Myeloma Patients. Advances in hematology (Online). 517561. 2011
- Comparison of Short-Term Response and Long-Term Outcomes After Initial Systemic Treatment of Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation. 17:124-132. 2011-01-01
- Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology.. Infectious Disease Clinics of North America. 24. 2010
- Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes.. Clinical Advances in Hematology and Oncology. 8. 2010
- Phase II Study of Bryostatin 1 and Vincristine for Aggressive Non-Hodgkin Lymphoma Relapsing After An Autologous Stem Cell Transplant. American Journal of Hematology. 84:484-487. 2009-08-01
- Non-Myeloablative Allogeneic Stem Cell Transplantation To Treat High Risk Heavily Pretreated Multiple. Biology of Blood and Marrow Transplantation. 14:69-70. 2008-02-01

principal investigator on

A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3)Therapy or Idarubicin With High Dose...... awarded by Southwest Oncology Group 2013 - 2018
An Open-Label Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator's Choice in awarded by Pfizer Inc 2013 - 2016
A Rmd, Prospective, D/B, Placebo-Controlled, Phase 3 Study of US-Atg-F Prophylaxis As a Supplement to Standard of Care awarded by Fresenius Biotech North America 2012 - 2015
Phase III Randomized Trial of Clofarabine As Induction and Post-Remission Therapy Vs. Standard Daunorubicin & . . . awarded by National Cancer Institute 2012 - 2014
A Phase III Randomized Double-blind Study of Induction (Daunorubicin/Cytarabine)and Consolidation (High Dose Cytarabin awarded by National Institutes of Health 2009 - 2018
E1900 - a Phase III Trial in Adult Acute Myeloid Leukemia: Daunorubicin Dose-Intensification & Gemtuzumab-Ozogamicin... awarded by National Institutes of Health 2002 - 2017
Clinical and Economic Impact of Upfront Plerixafor in Autologous Transplantation awarded by Genzyme Corporation 2011 - 2017
A Randomised Phase III Study of Elacytarabine Vs. Investigator's Choice in Patients With Late Stage Acute . . awarded by Clavis Pharma Asa 2010 - 2015
A Prospective, Randomized Trial Comparing the Efficacy of Anidulafungin and Voriconazole in Combination to That Of.... awarded by Pfizer Inc 2009 - 2012
Cooperative Group Outreach Program- E2902-Acute Myeloid Leukemia awarded by National Institutes of Health 2006 - 2012
E3999 a Randomized, Placebo-Controlled Double Blind Trial of the Administra..... awarded by National Institutes of Health 2005 - 2011
An Open Label Randomized Controlled Dose Escalating Phase Phase Dy of As1411 Combined With Cytarabine in The....... awarded by Inc Research Inc 2008 - 2009
Arsenic Trioxide in Primary Curative Apl Therapy awarded by National Institutes of Health
Randomized 2X2 Multi-Center, Opn-Lbl Ph2 Study of Bms-354825 Admn Oralat Dose of 50Mg or 70Mg 2X Daily or 100 Mg or 140 Mg Once... awarded by Bristol Myers Squibb Company Pharmacy Research Institute
Randomized Phase 3 Trial of Decitabine Versus Patients Choice With Physicians Advice of Either Supportive Care Or...... awarded by Mgi Pharma Inc

teaching activities

BCC7111 Fall 2010 8637 BCC7111 Fall 2010 8637
BCC7111 Spring 2010 8568 BCC7111 Spring 2010 8568
BCC7111 Spring 2011 8568 BCC7111 Spring 2011 8568
BMS6834 Spring 2011 6935 BMS6834 Spring 2011 6935
BMS6834 Summer 2009 8865 BMS6834 Summer 2009 8865
BMS6834 Summer 2010 8865 BMS6834 Summer 2010 8865
MEL7948 Fall 2008 2356 MEL7948 Fall 2008 2356
MEL7948 Fall 2009 2356 MEL7948 Fall 2009 2356
MEL7948 Spring 2009 8565 MEL7948 Spring 2009 8565
MEL7948 Spring 2010 8565 MEL7948 Spring 2010 8565
PAS5110 Spring 2010 0667 PAS5110 Spring 2010 0667
PAS5110 Summer 2010 0114 PAS5110 Summer 2010 0114

full name

Jack Hsu
Jack W Hsu

primary email

hsujw@medicine.ufl.edu

phone

(352) 392-3000
(352) 273-7832

Publications in VIVO

Co-author Network

Co-investigator Network

Contact Info

hsujw@medicine.ufl.edu

(352) 392-3000
(352) 273-7832